

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering
Cancer Center

[Find an MSK Doctor or Cancer Specialist](#)

[Make an Appointment](#)

[Patient & Caregiver Resources & Treatment](#)

[Refer a Patient](#)

ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Equality, diversity & inclusion](#)

[Annual report](#)

[Give to MSK](#)

Breast Cancer

[View all](#) 



[Dr. Chandarlapaty's Office Information](#) 



Languages: English

Request an Appointment

Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Call 646-497-9064

[Make an appointment](#)

About Me

What I Do at MSK

- Naddisy Foundation Chair in Breast Cancer Research at Memorial Sloan Kettering

Get To Know Me

I am a medical oncologist with a practice devoted to treating people with breast cancer.

I chose to focus on oncology because cancer is an enormous human problem and I wanted to help people who are affected by it. It has been my long-term desire to translate scientific discoveries into ways to treat disease and alleviate suffering.

[Read more](#)

+

My Role at MSK

A breast oncologist is a doctor with special training in breast cancer.

Areas of Expertise

My Specialties

Breast Cancer

Education & Honors

Education

MD, Wake Forest University School of Medicine

PhD, University of North Carolina at Chapel Hill (Biochemistry)

Residencies

Internal Medicine - New York Presbyterian Hospital

Awards and Honors

Castle Connolly: America's Top Doctor (2024)

Top Doctors New York Metro Area, Castle Connolly (2023)

Castle Connolly: America's Top Doctors (2023)

Fellowships

Hematology/Medical Oncology - Memorial Sloan Kettering Cancer Center

Board Certifications

Internal Medicine

Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage.](#)

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176).

Make an Appointment



New Patients

Scheduling an appointment is easy. Click or call [646-497-9064](tel:646-497-9064)— we're available Monday through Friday, 8 a.m. to 6 p.m. (Eastern time)

[Make an Appointment](#)

Current Patients

Request an appointment by logging on to MyMSK or calling your doctor's office. If you aren't registered for MyMSK, call [646-227-2593](tel:646-227-2593) for your Enrollment ID.

Contact and Location

Dr. Chandarlapaty sees patients at one location.


Office Phone

 [646-888-4311](tel:646-888-4311)

Location

 New York, NY

[Evelyn H. Lauder Breast Center](#)


 300 East 66th Street
Floors 1 - 4
New York, NY 10065
[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations.](#)

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. I work closely with nurse practitioner Bryn Vandermark and nurse Emer Heaney. We combine our expertise to provide comprehensive care to our patients at every step of their cancer journey.

Clinical Trials



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](#) →

Research and Publications

[View Dr. Chandarlapaty's Lab](#)

Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, Rosen N. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. *Cancer Cell*. 2011 Jan 18;19(1):58-71. doi: 10.1016/j.ccr.2010.10.031. Epub 2011 Jan 6. PMID: 21215704; PMCID: PMC3025058.

Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet*. 2013 Dec;45(12):1439-45. doi: 10.1038/ng.2822. Epub 2013 Nov 3. PMID: 24185512; PMCID: PMC3903423.

Toy W, Weir H, Razavi P, Lawson M, Goeppert AU, Mazzola AM, Smith A, Wilson J, Morrow C, Wong WL, De Stanchina E, Carlson KE, Martin TS, Uddin S, Li Z, Fanning S, Katzenellenbogen JA, Greene G, Baselga J, Chandarlapaty S. Activating *ESR1* Mutations Differentially Affect the Efficacy of ER Antagonists. *Cancer Discov*. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16. PMID: 27986707; PMCID: PMC5340622.

Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C, Hsieh W, Sanchez-Vega F, Brown DN, Da Cruz Paula AF, Morris L, Selenica P, Eichenberger E, Shen R, Schultz N, Rosen N, Scaltriti M, Brogi E, Baselga J, Reis-Filho JS, Chandarlapaty S. Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. *Cancer Cell*. 2018 Dec 10;34(6):893-905.e8. doi: 10.1016/j.ccell.2018.11.006. PMID: 30537512; PMCID: PMC6294301.

Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Won HH, Li BT, Shen R, Vasan N, Modi S, Jhaveri K, Caravella BA, Patil S, Selenica P, Zamora S, Cowan AM, Comen E, Singh A, Covey A, Berger MF, Hudis CA, Norton L, Nagy RJ, Odegaard JI, Lanman RB, Solit DB, Robson ME, Lacouture ME, Brogi E, Reis-Filho JS, Moynahan ME, Scaltriti M, Chandarlapaty S. Alterations in *PTEN* and *ESR1* promote clinical resistance to alpelisib plus aromatase inhibitors. *Nat Cancer*. 2020 Apr;1(4):382-393. doi: 10.1038/s43018-020-0047-1. Epub 2020 Mar 23. PMID: 32864625; PMCID: PMC7450824.

Li Q, Jiang B, Guo J, Shao H, Del Priore IS, Chang Q, Kudo R, Li Z, Razavi P, Liu B, Boghossian AS, Rees MG, Ronan MM, Roth

JA, Donovan KA, Palafox M, Reis-Filho JS, de Stanchina E, Fischer ES, Rosen N, Serra V, Koff A, Chodera JD, Gray NS, Chandarlapaty S. INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. *Cancer Discov.* 2022 Feb;12(2):356-371. doi: 10.1158/2159-8290.CD-20-1726. Epub 2021 Sep 20. PMID: 34544752; PMCID: PMC8831444.

Publications on PubMed

Visit PubMed for a full listing of Dr. Chandarlapaty's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed](#) →

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Sarat Chandarlapaty discloses the following relationships and financial interests:

Boxer Capital, LLC

Professional Services and Activities

Eli Lilly and Company

Professional Services and Activities

Encore Medical Education

Professional Services and Activities

Genesis Therapeutics

Professional Services and Activities

Gerson Lehrman Group

Professional Services and Activities

Novartis

Professional Services and Activities

Nuvalent, Inc.

Professional Services and Activities

Odyssey Biosciences

Equity; Fiduciary Role / Position; Intellectual Property Rights

Prelude Therapeutics

Professional Services and Activities

SAGA Diagnostics

Professional Services and Activities

Totus Medicines Inc.

Equity

eFFECTOR Therapeutics

Equity; Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#). For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org.

[View all disclosures](#) →

▼ Connect

[Contact us](#)

[Locations](#)

APPOINTMENTS

[800-525-2225](#)



▼ About MSK

[About us](#)

[Careers](#) ■

[Giving](#) ■

▼ Cancer Care

[Adult cancer types](#)

[Child & teen cancer types](#)

[Integrative medicine](#)

[Nutrition & cancer](#)

[Find a doctor](#)

▾ Research & Education

[Sloan Kettering Institute](#)

[Gerstner Sloan Kettering Graduate School](#) ■

[Graduate medical education](#)

[MSK Library](#) ■

[Communication preferences](#)

[Cookie preferences](#)

[Legal disclaimer](#)

[Accessibility statement](#)

[Privacy policy](#)

[Price transparency](#)

[Public notices](#)

© 2024 Memorial Sloan Kettering Cancer Center